Argenx price target raised to $1,100 from $775 at Guggenheim

Guggenheim raised the firm’s price target on Argenx (ARGX) to $1,100 from $775 and keeps a Buy rating on the shares. Argenx has set “clear and bold goals with their 2030 agenda,” which include reaching 50,000 patients on treatment in 10 labeled indications and bringing five new molecules to Phase 3 by 2030, notes the analyst. The firm’s analysis suggests the company could “nearly double its market capitalization” within five years, the analyst tells investors.